Prosecution Insights
Last updated: November 04, 2026
Application No. 18/294,389

CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF

Final Rejection §103§112
Filed
Feb 01, 2024
Priority
Aug 03, 2021 — provisional 63/228,665 +1 more
Examiner
KIFLE, BRUCK
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mitochondria Emotion Inc.
OA Round
2 (Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1383 granted / 1745 resolved
+19.3% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
45 currently pending
Career history
1791
Total Applications
across all art units

Statute-Specific Performance

§101
5.9%
-34.1% vs TC avg
§103
12.6%
-27.4% vs TC avg
§102
12.1%
-27.9% vs TC avg
§112
53.9%
+13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1745 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendments and remarks filed August 12, 2026 have been received and reviewed. Claims 1, 2, 8-11, 18-21 and 27-29 are now pending in this application. Claim Rejections - 35 USC § 112 Claims 2 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. ii) Claim 2 is still unclear. There is no selection of Y and b that results in anything but a 5- or 6-atom bridge (a is always 0). Thus, the claim fails to narrow claim 1 any further. Deletion of claim 2 is suggested. iii) In claim 20, the compound of claim 1 should be present in “an effective amount” for the pharmaceutical composition to work. Appropriate insertion of this phrase is suggested. Applicants have neither amended the claim nor argued that a pharmaceutical composition lacking an effective amount of the compound of claim 1 is useful. Claims 21 and 27-29 are again rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The basis of this rejection is the same as given in the previous office action and is incorporated herein fully by reference. Applicants’ arguments and amendments have been fully considered but not found persuasive because the skilled artisan should be able to say for sure which disease, disorder or condition is somewhat associated with mitochondria or responsive to mitofusin modulation. The clinician must know what diseases and what symptoms are to be prevented or treated by claims 21 and 25. The rejection of claims 27 and 28 also remain for the reasons given in the previous office action which have not been addressed. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1, 2, 8-11, 18-21 and 27-29 are rejected under 35 U.S.C. 103 as being unpatentable over Zhuo et al. (WO 2007/103719). The reference teaches the compound depicted below. RN 948555-52-0 CAPLUS CN Cyclohexanecarboxamide, 3-[(4-ethoxyphenyl)methyl]-N-(trans-4- hydroxycyclohexyl)- (CA INDEX NAME) PNG media_image1.png 228 538 media_image1.png Greyscale . The claims differ from this prior art compound by the length of the linking carbon chain between the cyclohexane and phenyl. However, it has been long established that structural relationship varying the size of a linking carbon chain - is per se obvious. Specifically, In re Shetty, 195 USPQ 753, In re Wilder, 195 USPQ 426 and Ex Parte Greshem 121 USPQ 422 all feature a compound with a C2 link rejected over a compound with a C1 link. Similarly, In re Chupp, 2 USPQ 2nd 1437 and In re Coes, 81 USPQ 369 have a C1 link unpatentable over a C2 link. Ex parte Ruddy 121 USPQ 427 has a C3 link unpatentable over a C1 link. Ex parte Nathan, 121 USPQ 349 found the insertion of a C2H4 link obvious. In all of these cases, the variation was per-se obvious and did not require a specific teaching. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRUCK KIFLE whose telephone number is (571)272-0668. The examiner can normally be reached 8 AM - 6 PM, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. October 2, 2026 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Feb 01, 2024
Application Filed
May 15, 2026
Non-Final Rejection mailed — §103, §112
Aug 12, 2026
Response Filed
Oct 06, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780782
Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof
3y 11m to grant Granted Nov 03, 2026
Patent 12780855
PHOSPHAPHENALENE-GOLD(I) COMPLEXES AS CHEMOTHERAPEUTIC AGENTS AGAINST GLIOBLASTOMA
3y 6m to grant Granted Nov 03, 2026
Patent 12766146
Salts and Solid Form of a BTK Inhibitor
4y 5m to grant Granted Oct 20, 2026
Patent 12767637
MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES
3y 11m to grant Granted Oct 20, 2026
Patent 12765555
METHOD FOR CONTROLLING WEEDS
3y 3m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.9%)
1y 10m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1745 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month